To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - New director appointments and changes to board committees

Release Date: 27/07/2021 15:00
Code(s): MEI     PDF:  
Wrap Text
New director appointments and changes to board committees

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, or the “Company” or the “Group”)

27 July 2021

NEW DIRECTOR APPOINTMENTS AND CHANGES TO BOARD COMMITTEES

Mediclinic, a leading diversified international private healthcare services group, announces the
appointment of two new independent non-executive directors: Natalia Barsegiyan and Zarina Bassa.

Dame Inga Beale, Chair of Mediclinic, commented: “The Board is delighted to welcome Natalia and
Zarina as independent non-executive directors of the Company. Each will bring significant and diverse
skills and experience, complementing those of existing Board members. I am confident they will both
be great additions to our Board of Directors.”

Natalia Barsegiyan is currently a non-executive director of Domino’s Pizza Group plc, the FTSE 250
digitally-enabled, quick service international restaurant group and is a member of their Audit Committee.
She also acts as an adviser to Kharis Capital, a private equity firm based in Belgium. Prior to this, the
majority of Natalia’s career was with the US group Yum! Brands, Inc., owner of a portfolio of many well-
known brands such as KFC, Pizza Hut and Taco Bell, where she served as Chief Commercial Officer
of the Group and then Chief Financial Officer of Taco Bell. Her appointment as a director of Mediclinic
will become effective on 1 August 2021. Natalia will bring a strong finance background with a
commercial and strategic focus, an in-depth understanding of the use of data analytics to support
transformation and broad international experience, having lived and worked across the US, Europe,
Russia and the UK.

Zarina Bassa is currently the senior independent director of Investec plc and Investec Ltd, the specialist
banking and wealth management group with a dual listed company structure and listings on the London
and Johannesburg Stock Exchanges; lead independent director of Woolworths Holdings Ltd; and non-
executive director of JSE Ltd and Oceana Group Ltd (the last three all being South African companies
with a listing on the Johannesburg Stock Exchange). Zarina has stepped down today as Chair of Yebo
Yethu Ltd and previously served as a non-executive director at several other companies including
Kumba Iron Ore Ltd; Mercedes Benz SA Ltd; Sun International Ltd; Vodacom South Africa Proprietary
Limited; the South African Institute of Chartered Accountants; and the Financial Services Board. Prior
to that, she was a partner of Ernst & Young Inc. and then joined the Absa Group in 2002, where she
served as an executive director of Absa Bank, a member of the group’s executive committee, and Head
of the Private Bank. Zarina’s appointment as a director of Mediclinic will become effective on 1 February
2022. The Board of Mediclinic has carefully considered Zarina’s existing time commitments and is
satisfied that she will have sufficient time to dedicate to fulfil her responsibilities to the Group. She will
contribute strategic and operational experience in complex, regulated environments, a strong financial
and accounting background, and diverse experience in listed companies across a breadth of sectors
and jurisdictions.

CHANGES TO BOARD COMMITTEES

Following a review of the Board Committee structure and responsibilities, the Board has decided to
separate the responsibilities of the Clinical Performance and Sustainability Committee, to allow for more
time to dedicate to the oversight of these key aspects of the Group’s strategy and operations.

Accordingly, with effect from 1 September 2021:
• the Clinical Performance and Sustainability Committee will become a focused Clinical Performance
  Committee. There will be no change in its composition; and
• a new Environmental, Social and Governance Committee will be established, chaired by Dame
  Inga, with other members comprising: Dr Ronnie van der Merwe, Natalia Barsegiyan, Dr Felicity
  Harvey and Danie Meintjes.

In addition:
• Natalia Barsegiyan will also join the Audit and Risk Committee upon her appointment as a non-
  executive director;
• Zarina Bassa will join the Audit and Risk and Remuneration Committees when her appointment as
  non-executive director becomes effective;
• Dr Muhadditha Al Hashimi will join the Remuneration Committee on 13 September 2021; and
• Tom Singer will join the Investment Committee on 13 September 2021.

Other changes to roles and responsibilities of other directors will also proceed as announced by the
Company on 26 May 2021.

This announcement is made in accordance with the requirement of LR 9.6.11. There are no disclosures
required pursuant to paragraphs (1) to (6) of LR 9.6.13 R of the United Kingdom Listing Authority's
Listing Rules in respect of these appointments.

About Mediclinic International plc

Mediclinic is a diversified international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab
Emirates (“UAE”).

The Group’s core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum
of care in such a way that the Group will be regarded as the most respected and trusted provider of
healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of
its markets.

At 1 July 2021, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities,
18 day case clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals and four day case
clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operations
included 50 hospitals (three of which in Namibia), five sub-acute hospitals, two mental health facilities
and 12 day case clinics (four of which operated by Intercare) across South Africa, and around 8 600
inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 18
outpatient clinics with more than 900 inpatient beds in the UAE. In addition, under management
contracts, Mediclinic Middle East operates one hospital in Abu Dhabi and will open a 200-bed hospital
in the Kingdom of Saudi Arabia in mid-2022.

The Company’s primary listing is on the LSE in the UK, with secondary listings on the JSE in South
Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the United Kingdom and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Ben Atwell/Ciara Martin – United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment
Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

Date: 27-07-2021 03:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story